Jeremy Everett is the Professor of Pharmaceutical Technologies at the University of Greenwich UK. In addition, he is a Visiting Professor in the Department of Surgery and Cancer at Imperial College and at the Lee Kong Chian School of Medicine at Nanyang Technological University, Singapore, where he is also a Scientific Consultant and Acting Director of the Singapore Phenome Centre.
He previously held a variety of global drug discovery technology leadership positions for Pfizer, and before that, SmithKline Beecham, including responsibility for drug target analysis, drug design, drug lead generation, analytical sciences, biobanking, screening file management, high throughput screening (HTS), and structural biology. He is a consultant on drug discovery to both large pharma and small research institutes, and also consults on pharmaceutical patent litigation.
Jeremy conducts research in metabonomics and pharmaco-metabonomics, in which he has worked for over 30 years, including co-naming and defining both areas. He is a co-discoverer of pharmacometabonomics in animals and humans. Current work is focused on genotype – metabotype correlations in the areas of colorectal cancer, obesity and diabetes in collaborations with Horizon Discovery, UK and University College, London respectively.
Jeremy received both his BSc and PhD in chemistry from Nottingham University, UK. He did post-doctoral studies at McMaster University and at McGill University in Canada.
Jeremy is a Fellow of the Royal Society of Chemistry and a Chartered Chemist, a Member of the American Chemical Society, a Fellow of the Higher Education Academy and is an author or co-author on 95 peer-reviewed publications and several patents, with over 3,600 citations to date and an h-index of 25. He has delivered over 60 invited lectures.